Delenex Expands Pipeline

Delenex has generated an anti-IL-17A PENTRABody for the treatment of dermatological and other inflammatory diseases. IL-17A is a pivotal interleukin which has been shown to play a key role in such medical conditions. Systemic administration of anti-IL-17A IgGs is an effective treatment of psoriasis, psoriatic arthritis and other diseases. The small size and its extraordinary neutralizing potency allow a unique positioning as compared to other anti-IL-17A treatments currently in clinical development.

Delenex’ lead candidate neutralizing IL-1β is a PENTRABody for the treatment of acne and other inflammatory diseases such as gouty arthritis. IL-1β has been shown to be overexpressed in lesions of acne and to be a key mediator of skin inflammation in this disease that affects a substantial fraction of the population and demands innovative treatment modalities, especially in case of moderate-to-severe forms of acne. In gout, the high potency and small size allow the application of this PENTRABody especially for the treatment of gout flares, where a fast onset and short action of the drug is required.

“The identification of such highly potent PENTRABodies in a short period of time proves once again the power of our technology. PENTRABodies are uniquely positioned vis-à-vis existing therapies and address the increasing demand for therapies that combine high potency with a favorable safety profile and cost-efficiency”, commented Titus Kretzschmar, PhD, Chief Scientific Officer at Delenex.

About Delenex Therapeutics AG
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company). Delenex is a privately-held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex’ proprietary PENTRABodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body.